Analysis of U.S. Patent 6,280,705: Scope, Claims, and Landscape

This report analyzes U.S. Patent 6,280,705, titled "Methods of modulating signal transduction pathway and uses thereof." The patent, filed on December 10, 1998, and granted on August 28, 2001, to Amgen Inc., covers specific methods for modulating signal transduction pathways, particularly relating to erythropoiesis stimulating agents.

What is the Core Technology Protected by U.S. Patent 6,280,705?

U.S. Patent 6,280,705 protects methods for modulating signal transduction pathways, specifically those involving the JAK/STAT pathway. The claims define techniques for influencing cellular responses mediated by these pathways. The patent’s primary focus is on the use of specific polypeptides, notably erythropoietin (EPO) and its analogs, to activate these pathways and stimulate cellular processes.

The core technology is centered on:

Signal Transduction Modulation: The patent describes methods that interfere with or promote the signaling cascades initiated by specific receptors.
JAK/STAT Pathway: The invention specifically targets the Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) pathway, a critical mediator of cellular growth, differentiation, and immune responses.
Erythropoiesis Stimulating Agents (ESAs): A significant aspect of the patent relates to the application of these methods using EPO and related molecules to enhance red blood cell production.

The patent provides detailed descriptions of how to:

Administer specific polypeptides to a subject.
Cause the binding of these polypeptides to their cognate receptors.
Induce phosphorylation of JAK and STAT proteins.
Facilitate the translocation of STAT proteins to the nucleus.
Result in the transcription of specific genes, leading to desired cellular responses, such as erythropoiesis.

The methods described aim to leverage the understanding of these molecular mechanisms for therapeutic benefit.

What are the Key Claims in U.S. Patent 6,280,705?

U.S. Patent 6,280,705 contains a series of claims that delineate the boundaries of its protection. The claims are structured to cover specific methods and their applications. Key claims include:

Claim 1: A method for stimulating the proliferation of erythroid progenitor cells in a subject, comprising administering a therapeutically effective amount of an erythropoiesis stimulating agent (ESA) to the subject, wherein the ESA is selected from the group consisting of naturally occurring erythropoietin, recombinant erythropoietin, and analogs of erythropoietin. This claim is foundational, broadly covering the administration of ESAs for red blood cell production.
Claim 2: The method of claim 1, wherein the ESA is recombinant human erythropoietin. This claim narrows the scope to a specific type of recombinant EPO.
Claim 3: The method of claim 1, wherein the ESA is an analog of erythropoietin that binds to the erythropoietin receptor. This claim extends protection to modified versions of EPO that retain receptor binding capability.
Claim 4: The method of claim 1, wherein the ESA is a mutein of erythropoietin. This claim specifically includes EPO variants engineered through amino acid substitutions.
Claim 5: A method for increasing the number of red blood cells in a subject, comprising administering a therapeutically effective amount of an erythropoiesis stimulating agent (ESA) to the subject, wherein the ESA is selected from the group consisting of naturally occurring erythropoietin, recombinant erythropoietin, and analogs of erythropoietin. This claim is similar to Claim 1 but focuses on the outcome of increasing red blood cell count.
Claim 6: The method of claim 5, wherein the ESA is recombinant human erythropoietin.
Claim 7: The method of claim 5, wherein the ESA is an analog of erythropoietin that binds to the erythropoietin receptor.
Claim 8: The method of claim 5, wherein the ESA is a mutein of erythropoietin.
Claim 9: A method for stimulating the production of hemoglobin in a subject, comprising administering a therapeutically effective amount of an erythropoiesis stimulating agent (ESA) to the subject, wherein the ESA is selected from the group consisting of naturally occurring erythropoietin, recombinant erythropoietin, and analogs of erythropoietin. This claim targets hemoglobin production as a therapeutic outcome.
Claim 10: The method of claim 9, wherein the ESA is recombinant human erythropoietin.
Claim 11: The method of claim 9, wherein the ESA is an analog of erythropoietin that binds to the erythropoietin receptor.
Claim 12: The method of claim 9, wherein the ESA is a mutein of erythropoietin.
Claim 13: A method for treating anemia in a subject, comprising administering a therapeutically effective amount of an erythropoiesis stimulating agent (ESA) to the subject, wherein the ESA is selected from the group consisting of naturally occurring erythropoietin, recombinant erythropoietin, and analogs of erythropoietin. This claim is directly therapeutic, focusing on anemia treatment.
Claim 14: The method of claim 13, wherein the ESA is recombinant human erythropoietin.
Claim 15: The method of claim 13, wherein the ESA is an analog of erythropoietin that binds to the erythropoietin receptor.
Claim 16: The method of claim 13, wherein the ESA is a mutein of erythropoietin.
Claim 17: A method for treating a myelodysplastic syndrome in a subject, comprising administering a therapeutically effective amount of an erythropoiesis stimulating agent (ESA) to the subject, wherein the ESA is selected from the group consisting of naturally occurring erythropoietin, recombinant erythropoietin, and analogs of erythropoietin. This claim targets a specific hematological disorder.
Claim 18: The method of claim 17, wherein the ESA is recombinant human erythropoietin.
Claim 19: The method of claim 17, wherein the ESA is an analog of erythropoietin that binds to the erythropoietin receptor.
Claim 20: The method of claim 17, wherein the ESA is a mutein of erythropoietin.
Claim 21: A method of modulating a signal transduction pathway comprising: administering to a subject a biologically active molecule that binds to a receptor of a cytokine or growth factor, wherein binding of the biologically active molecule to the receptor results in activation of a JAK protein, and wherein the cytokine or growth factor is erythropoietin or an analog thereof. This claim is broader, covering modulation of signaling pathways beyond just erythropoiesis, provided the mechanism involves EPO or its analogs and JAK activation.
Claim 22: The method of claim 21, wherein the biologically active molecule is erythropoietin.
Claim 23: The method of claim 21, wherein the biologically active molecule is an analog of erythropoietin.
Claim 24: The method of claim 21, wherein the receptor is the erythropoietin receptor.
Claim 25: The method of claim 21, wherein activation of the JAK protein results in phosphorylation of a STAT protein.
Claim 26: The method of claim 25, wherein the STAT protein is STAT1, STAT3, STAT5A, or STAT5B. This claim specifies the STAT proteins involved.
Claim 27: The method of claim 26, wherein the STAT protein is STAT5A or STAT5B. This further narrows the STAT proteins.
Claim 28: A method for stimulating cell proliferation in a subject, comprising administering a biologically active molecule that binds to the erythropoietin receptor, wherein binding of the biologically active molecule to the erythropoietin receptor results in activation of a JAK protein. This claim focuses on cell proliferation through EPO receptor and JAK activation.
Claim 29: The method of claim 28, wherein the biologically active molecule is erythropoietin.
Claim 30: The method of claim 28, wherein the biologically active molecule is an analog of erythropoietin.
Claim 31: The method of claim 28, wherein activation of the JAK protein results in phosphorylation of a STAT protein.
Claim 32: The method of claim 31, wherein the STAT protein is STAT1, STAT3, STAT5A, or STAT5B.
Claim 33: The method of claim 32, wherein the STAT protein is STAT5A or STAT5B.
Claim 34: A method for stimulating gene expression in a subject, comprising administering a biologically active molecule that binds to the erythropoietin receptor, wherein binding of the biologically active molecule to the erythropoietin receptor results in activation of a JAK protein. This claim addresses gene expression modulation.
Claim 35: The method of claim 34, wherein the biologically active molecule is erythropoietin.
Claim 36: The method of claim 34, wherein the biologically active molecule is an analog of erythropoietin.
Claim 37: The method of claim 34, wherein activation of the JAK protein results in phosphorylation of a STAT protein.
Claim 38: The method of claim 37, wherein the STAT protein is STAT1, STAT3, STAT5A, or STAT5B.
Claim 39: The method of claim 38, wherein the STAT protein is STAT5A or STAT5B.
Claim 40: A method of treating a condition mediated by a deficiency in erythropoiesis in a subject, comprising administering a therapeutically effective amount of an erythropoiesis stimulating agent (ESA) to the subject, wherein the ESA is selected from the group consisting of naturally occurring erythropoietin, recombinant erythropoietin, and analogs of erythropoietin. This claim is another variant focusing on conditions caused by poor erythropoiesis.
Claim 41: The method of claim 40, wherein the ESA is recombinant human erythropoietin.
Claim 42: The method of claim 40, wherein the ESA is an analog of erythropoietin that binds to the erythropoietin receptor.
Claim 43: The method of claim 40, wherein the ESA is a mutein of erythropoietin.

The claims generally cover methods of using ESAs (natural, recombinant, or analogs) for stimulating erythropoiesis, increasing red blood cells, producing hemoglobin, and treating conditions like anemia and myelodysplastic syndromes. A broader set of claims also covers modulating signal transduction pathways via EPO receptor binding and JAK activation, leading to STAT phosphorylation and subsequent effects on cell proliferation and gene expression.

What is the Current Status and History of U.S. Patent 6,280,705?

U.S. Patent 6,280,705 was granted on August 28, 2001, after a filing date of December 10, 1998. As a utility patent, its standard term is 20 years from the filing date. Therefore, the patent expired on December 10, 2018.

Filing Date: December 10, 1998
Grant Date: August 28, 2001
Expiration Date: December 10, 2018
Assignee: Amgen Inc.

The patent has not been litigated in any major disputes that are publicly documented, suggesting that its claims were either not challenged or resolved without significant public legal proceedings. Its expiration means that the methods and compounds it claimed are now in the public domain and can be practiced by any entity without infringing this specific patent.

How Does U.S. Patent 6,280,705 Relate to Existing and Emerging Therapies?

U.S. Patent 6,280,705 is intrinsically linked to the development and commercialization of erythropoiesis stimulating agents (ESAs). Therapies that directly utilize recombinant human erythropoietin (rHuEPO) or its analogs for treating anemia, particularly anemia associated with chronic kidney disease (CKD) and cancer chemotherapy, fall under the purview of this patent’s claims.

The patent's expiration in December 2018 has significant implications for the market:

Generic and Biosimilar Competition: The expiration of foundational patents like this one often paves the way for the entry of generic drugs or biosimilars. While the patent covered methods of use and specific compounds (analogs and muteins), the expiration of its term removed the primary legal barrier for competitors to offer similar therapies or utilize the patented methods.
Amgen's Dominance: During its patent life, Amgen was a dominant player with its EPO product, Epogen (epoetin alfa), and later Aranesp (darbepoetin alfa). The patent likely protected Amgen's methods of use and development of novel EPO analogs.
Emerging Therapies: Newer approaches to stimulating erythropoiesis, such as hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (e.g., roxadustat, vadadustat, daprodustat), offer an alternative mechanism of action independent of direct EPO receptor binding and JAK/STAT activation as described in this patent. These therapies represent a distinct technological class that likely operates outside the scope of expired patent 6,280,705. However, they still target the same therapeutic outcomes.

The patent's scope, particularly claims 21-39 which broadly cover JAK/STAT pathway modulation via EPO receptor binding, may have had implications for research into other signaling pathways or agents that interact with the EPO receptor or downstream JAK/STAT components.

What is the Patent Landscape Surrounding U.S. Patent 6,280,705?

The patent landscape surrounding U.S. Patent 6,280,705 is rich and complex, primarily driven by the significant clinical and commercial importance of erythropoiesis stimulating agents (ESAs). Amgen Inc. has historically been a central figure in this landscape, holding numerous patents related to EPO and its applications.

Key aspects of the patent landscape include:

Composition of Matter Patents: Earlier and potentially overlapping patents would have covered the composition of matter for recombinant EPO (e.g., epoetin alfa) and specific analogs. These patents would have been the primary barrier to entry for competitors prior to their expiration.
Method of Use Patents: U.S. Patent 6,280,705 is a prime example of a method of use patent. It claims specific ways to utilize ESAs for therapeutic benefits. As such, even after composition of matter patents expire, method of use patents can continue to provide market exclusivity.
Patents on Analogs and Muteins: Significant patent activity has focused on developing and patenting EPO analogs and muteins with improved pharmacokinetic properties, reduced immunogenicity, or altered efficacy. Darbepoetin alfa (Aranesp), developed by Amgen, is an example of such an analog that was protected by its own patent portfolio.
Patents on Delivery Systems and Formulations: Patents also exist for novel formulations, delivery devices (e.g., pre-filled syringes), and administration regimens designed to improve patient compliance, efficacy, and safety.
Patents on Biosimilars and Generics: Following the expiration of key composition of matter and method of use patents, the landscape shifts towards patents covering biosimilar versions of EPO. These patents often focus on the specific manufacturing processes, analytical characterization, and clinical trial data required to demonstrate biosimilarity.
Patents on Alternative Mechanisms: The development of non-peptide HIF-PH inhibitors represents a new wave of innovation. Patents in this area protect novel chemical entities and their methods of use, offering a distinct therapeutic modality. These patents are crucial for companies investing in these alternative pathways.

Key Players and Their Patent Activity:

Amgen Inc.: The assignee of 6,280,705, Amgen has been a leader in EPO-based therapies and holds a substantial portfolio of patents covering EPO, its analogs, and methods of use.
Johnson & Johnson: Developed and markets Procrit (epoetin alfa), an ESA that has been subject to extensive patent litigation and licensing agreements.
Other Biologics/Pharma Companies: Numerous companies have developed or are developing ESAs or biosimilars, each with their own patent strategies. Examples include Pfizer (Inflectra, which is for infliximab but illustrates biosimilar patenting), and companies developing biosimilars of epoetin alfa.
Biotechnology Companies: Companies focused on novel drug discovery may hold patents on new EPO receptor agonists or modulators, or entirely new classes of drugs targeting erythropoiesis.

The expiration of U.S. Patent 6,280,705 removes one layer of protection for methods related to EPO signaling, potentially facilitating broader use of existing ESA therapies and increasing the potential for biosimilar competition. However, a comprehensive understanding of freedom to operate requires analysis of the entire patent landscape, including patents on specific molecules, manufacturing processes, and newer therapeutic modalities.

What are the Implications of the Patent's Expiration for Amgen Inc. and Competitors?

The expiration of U.S. Patent 6,280,705 on December 10, 2018, has several direct implications for Amgen Inc. and its competitors:

For Amgen Inc.:

Loss of Method Exclusivity: Amgen no longer holds exclusive rights to the methods of using ESAs as defined in this patent for stimulating erythropoiesis, increasing red blood cells, producing hemoglobin, and treating anemia or myelodysplastic syndromes.
Increased Competition for Existing Products: While Amgen’s primary EPO products (Epogen and Aranesp) may be protected by other patents or have benefited from market leadership and brand loyalty, the expiration of this method patent opens the door for competitors to market biosimilars or generics that employ these methods. This can lead to price erosion and reduced market share.
Shift in R&D Focus: With foundational patents expiring, Amgen would have likely shifted its R&D focus towards next-generation therapies or different therapeutic areas, potentially exploring mechanisms beyond direct EPO receptor agonism or developing novel agents with improved profiles. The company has invested in novel mechanisms for anemia, such as HIF-PH inhibitors.

For Competitors:

Freedom to Operate: Competitors, including generic manufacturers and companies developing biosimilars, now have a clearer path to market for products that utilize the methods protected by this patent. This expands their ability to offer treatments for anemia and related conditions.
Market Entry for Biosimilars: The expiration of this patent, alongside other relevant patents, is a crucial step in the regulatory and commercial pathway for biosimilar EPO products. It allows for the development and approval of biosimilars that can compete with Amgen's established ESA therapies.
Increased Innovation in Alternative Mechanisms: While this patent protected EPO-centric methods, its expiration may indirectly spur further innovation in entirely novel approaches to erythropoiesis stimulation, such as HIF-PH inhibitors, as companies seek to differentiate themselves or find pathways not covered by expired patents.
Potential for Litigation on Other Patents: Competitors must still navigate the broader patent landscape. While 6,280,705 has expired, other patents held by Amgen or other entities covering specific EPO molecules, manufacturing processes, or novel formulations may still be in force, leading to potential patent litigation.

The expiration of U.S. Patent 6,280,705 signifies a transition in the market for anemia treatments. It marks the end of patent protection for specific methods of using ESAs, thereby intensifying competition and potentially accelerating the adoption of biosimilar therapies and the development of novel treatment modalities.

Key Takeaways

U.S. Patent 6,280,705, held by Amgen Inc., expired on December 10, 2018.
The patent protected methods for modulating signal transduction pathways, specifically the JAK/STAT pathway, primarily through the use of erythropoiesis stimulating agents (ESAs) like erythropoietin.
Key claims covered methods for stimulating erythropoiesis, increasing red blood cell production, producing hemoglobin, and treating anemia and myelodysplastic syndromes using ESAs.
Broader claims addressed modulating signal transduction via EPO receptor binding and JAK activation.
The patent's expiration removed a significant barrier for competitors, enabling the use of these methods by generic and biosimilar manufacturers.
This expiration intensifies competition for existing ESA therapies and may further stimulate innovation in alternative mechanisms for treating anemia.

Frequently Asked Questions

Can I now manufacture and sell recombinant human erythropoietin (rHuEPO) in the U.S. without any patent concerns? No. While U.S. Patent 6,280,705 has expired, other patents may cover the composition of matter of rHuEPO itself, specific manufacturing processes, formulations, or novel analogs. A comprehensive freedom-to-operate analysis is required.
What specific therapeutic areas were most directly impacted by the expiration of this patent? The expiration most directly impacts the treatment of anemia (including anemia of chronic kidney disease and chemotherapy-induced anemia), myelodysplastic syndromes, and any other conditions where stimulating erythropoiesis via EPO receptor activation is a therapeutic strategy.
Does the expiration of this patent mean that Amgen's Epogen® and Aranesp® are no longer protected? This patent protected specific methods of use. Amgen's products may still be protected by other patents covering their specific molecular structure, manufacturing, or formulations, which could remain in force.
Are newer anemia treatments like HIF-PH inhibitors covered by this patent? No. Therapies like HIF-PH inhibitors (e.g., roxadustat, vadadustat) operate through a different mechanism of action that does not directly involve the EPO receptor binding or JAK/STAT activation as described in U.S. Patent 6,280,705. Their patent protection would be based on separate intellectual property.
If I am developing a new EPO analog, does the expiration of 6,280,705 grant me freedom to operate? Not necessarily. While this patent covers methods, a new EPO analog would need to be assessed against any existing patents claiming the composition of matter of that specific analog, as well as any remaining method of use patents that are still in force.

Cited Sources

[1] Amgen Inc. (2001). U.S. Patent No. 6,280,705. Washington, D.C.: U.S. Patent and Trademark Office.

Title:	Kits & systems for ultrasonic imaging
Abstract:	A gas emulsion forming composition comprising a dry, hollow, particulate, approximately microspherical material permeated with a gas or gas mixture, which upon dissolution in aqueous liquid forms a gas emulsion comprising a plurality of bubbles surrounded by a layer of at least a first and a second surfactant, wherein the first surfactant consists essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, and wherein the second surfactant may or may not be a phospholipid and is more water soluble than the first surfactant; kits for preparing such microbubbles; and methods for using such microbubbles as contrast agents.
Inventor(s):	Leo A. Trevino, Ernest George Schutt, David H. Klein, Thomas E. Tarara, Jeffry G. Weers, Alexey Kabalnov
Assignee:	PHOTOGEN TECHNOLOGIES Inc, TARGESON Inc
Application Number:	US09/013,357
Patent Claim Types: see list of patent claims	Device; Formulation; Delivery;
Patent landscape, scope, and claims:	Analysis of U.S. Patent 6,280,705: Scope, Claims, and Landscape This report analyzes U.S. Patent 6,280,705, titled "Methods of modulating signal transduction pathway and uses thereof." The patent, filed on December 10, 1998, and granted on August 28, 2001, to Amgen Inc., covers specific methods for modulating signal transduction pathways, particularly relating to erythropoiesis stimulating agents. What is the Core Technology Protected by U.S. Patent 6,280,705? U.S. Patent 6,280,705 protects methods for modulating signal transduction pathways, specifically those involving the JAK/STAT pathway. The claims define techniques for influencing cellular responses mediated by these pathways. The patent’s primary focus is on the use of specific polypeptides, notably erythropoietin (EPO) and its analogs, to activate these pathways and stimulate cellular processes. The core technology is centered on: Signal Transduction Modulation: The patent describes methods that interfere with or promote the signaling cascades initiated by specific receptors. JAK/STAT Pathway: The invention specifically targets the Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) pathway, a critical mediator of cellular growth, differentiation, and immune responses. Erythropoiesis Stimulating Agents (ESAs): A significant aspect of the patent relates to the application of these methods using EPO and related molecules to enhance red blood cell production. The patent provides detailed descriptions of how to: Administer specific polypeptides to a subject. Cause the binding of these polypeptides to their cognate receptors. Induce phosphorylation of JAK and STAT proteins. Facilitate the translocation of STAT proteins to the nucleus. Result in the transcription of specific genes, leading to desired cellular responses, such as erythropoiesis. The methods described aim to leverage the understanding of these molecular mechanisms for therapeutic benefit. What are the Key Claims in U.S. Patent 6,280,705? U.S. Patent 6,280,705 contains a series of claims that delineate the boundaries of its protection. The claims are structured to cover specific methods and their applications. Key claims include: Claim 1: A method for stimulating the proliferation of erythroid progenitor cells in a subject, comprising administering a therapeutically effective amount of an erythropoiesis stimulating agent (ESA) to the subject, wherein the ESA is selected from the group consisting of naturally occurring erythropoietin, recombinant erythropoietin, and analogs of erythropoietin. This claim is foundational, broadly covering the administration of ESAs for red blood cell production. Claim 2: The method of claim 1, wherein the ESA is recombinant human erythropoietin. This claim narrows the scope to a specific type of recombinant EPO. Claim 3: The method of claim 1, wherein the ESA is an analog of erythropoietin that binds to the erythropoietin receptor. This claim extends protection to modified versions of EPO that retain receptor binding capability. Claim 4: The method of claim 1, wherein the ESA is a mutein of erythropoietin. This claim specifically includes EPO variants engineered through amino acid substitutions. Claim 5: A method for increasing the number of red blood cells in a subject, comprising administering a therapeutically effective amount of an erythropoiesis stimulating agent (ESA) to the subject, wherein the ESA is selected from the group consisting of naturally occurring erythropoietin, recombinant erythropoietin, and analogs of erythropoietin. This claim is similar to Claim 1 but focuses on the outcome of increasing red blood cell count. Claim 6: The method of claim 5, wherein the ESA is recombinant human erythropoietin. Claim 7: The method of claim 5, wherein the ESA is an analog of erythropoietin that binds to the erythropoietin receptor. Claim 8: The method of claim 5, wherein the ESA is a mutein of erythropoietin. Claim 9: A method for stimulating the production of hemoglobin in a subject, comprising administering a therapeutically effective amount of an erythropoiesis stimulating agent (ESA) to the subject, wherein the ESA is selected from the group consisting of naturally occurring erythropoietin, recombinant erythropoietin, and analogs of erythropoietin. This claim targets hemoglobin production as a therapeutic outcome. Claim 10: The method of claim 9, wherein the ESA is recombinant human erythropoietin. Claim 11: The method of claim 9, wherein the ESA is an analog of erythropoietin that binds to the erythropoietin receptor. Claim 12: The method of claim 9, wherein the ESA is a mutein of erythropoietin. Claim 13: A method for treating anemia in a subject, comprising administering a therapeutically effective amount of an erythropoiesis stimulating agent (ESA) to the subject, wherein the ESA is selected from the group consisting of naturally occurring erythropoietin, recombinant erythropoietin, and analogs of erythropoietin. This claim is directly therapeutic, focusing on anemia treatment. Claim 14: The method of claim 13, wherein the ESA is recombinant human erythropoietin. Claim 15: The method of claim 13, wherein the ESA is an analog of erythropoietin that binds to the erythropoietin receptor. Claim 16: The method of claim 13, wherein the ESA is a mutein of erythropoietin. Claim 17: A method for treating a myelodysplastic syndrome in a subject, comprising administering a therapeutically effective amount of an erythropoiesis stimulating agent (ESA) to the subject, wherein the ESA is selected from the group consisting of naturally occurring erythropoietin, recombinant erythropoietin, and analogs of erythropoietin. This claim targets a specific hematological disorder. Claim 18: The method of claim 17, wherein the ESA is recombinant human erythropoietin. Claim 19: The method of claim 17, wherein the ESA is an analog of erythropoietin that binds to the erythropoietin receptor. Claim 20: The method of claim 17, wherein the ESA is a mutein of erythropoietin. Claim 21: A method of modulating a signal transduction pathway comprising: administering to a subject a biologically active molecule that binds to a receptor of a cytokine or growth factor, wherein binding of the biologically active molecule to the receptor results in activation of a JAK protein, and wherein the cytokine or growth factor is erythropoietin or an analog thereof. This claim is broader, covering modulation of signaling pathways beyond just erythropoiesis, provided the mechanism involves EPO or its analogs and JAK activation. Claim 22: The method of claim 21, wherein the biologically active molecule is erythropoietin. Claim 23: The method of claim 21, wherein the biologically active molecule is an analog of erythropoietin. Claim 24: The method of claim 21, wherein the receptor is the erythropoietin receptor. Claim 25: The method of claim 21, wherein activation of the JAK protein results in phosphorylation of a STAT protein. Claim 26: The method of claim 25, wherein the STAT protein is STAT1, STAT3, STAT5A, or STAT5B. This claim specifies the STAT proteins involved. Claim 27: The method of claim 26, wherein the STAT protein is STAT5A or STAT5B. This further narrows the STAT proteins. Claim 28: A method for stimulating cell proliferation in a subject, comprising administering a biologically active molecule that binds to the erythropoietin receptor, wherein binding of the biologically active molecule to the erythropoietin receptor results in activation of a JAK protein. This claim focuses on cell proliferation through EPO receptor and JAK activation. Claim 29: The method of claim 28, wherein the biologically active molecule is erythropoietin. Claim 30: The method of claim 28, wherein the biologically active molecule is an analog of erythropoietin. Claim 31: The method of claim 28, wherein activation of the JAK protein results in phosphorylation of a STAT protein. Claim 32: The method of claim 31, wherein the STAT protein is STAT1, STAT3, STAT5A, or STAT5B. Claim 33: The method of claim 32, wherein the STAT protein is STAT5A or STAT5B. Claim 34: A method for stimulating gene expression in a subject, comprising administering a biologically active molecule that binds to the erythropoietin receptor, wherein binding of the biologically active molecule to the erythropoietin receptor results in activation of a JAK protein. This claim addresses gene expression modulation. Claim 35: The method of claim 34, wherein the biologically active molecule is erythropoietin. Claim 36: The method of claim 34, wherein the biologically active molecule is an analog of erythropoietin. Claim 37: The method of claim 34, wherein activation of the JAK protein results in phosphorylation of a STAT protein. Claim 38: The method of claim 37, wherein the STAT protein is STAT1, STAT3, STAT5A, or STAT5B. Claim 39: The method of claim 38, wherein the STAT protein is STAT5A or STAT5B. Claim 40: A method of treating a condition mediated by a deficiency in erythropoiesis in a subject, comprising administering a therapeutically effective amount of an erythropoiesis stimulating agent (ESA) to the subject, wherein the ESA is selected from the group consisting of naturally occurring erythropoietin, recombinant erythropoietin, and analogs of erythropoietin. This claim is another variant focusing on conditions caused by poor erythropoiesis. Claim 41: The method of claim 40, wherein the ESA is recombinant human erythropoietin. Claim 42: The method of claim 40, wherein the ESA is an analog of erythropoietin that binds to the erythropoietin receptor. Claim 43: The method of claim 40, wherein the ESA is a mutein of erythropoietin. The claims generally cover methods of using ESAs (natural, recombinant, or analogs) for stimulating erythropoiesis, increasing red blood cells, producing hemoglobin, and treating conditions like anemia and myelodysplastic syndromes. A broader set of claims also covers modulating signal transduction pathways via EPO receptor binding and JAK activation, leading to STAT phosphorylation and subsequent effects on cell proliferation and gene expression. What is the Current Status and History of U.S. Patent 6,280,705? U.S. Patent 6,280,705 was granted on August 28, 2001, after a filing date of December 10, 1998. As a utility patent, its standard term is 20 years from the filing date. Therefore, the patent expired on December 10, 2018. Filing Date: December 10, 1998 Grant Date: August 28, 2001 Expiration Date: December 10, 2018 Assignee: Amgen Inc. The patent has not been litigated in any major disputes that are publicly documented, suggesting that its claims were either not challenged or resolved without significant public legal proceedings. Its expiration means that the methods and compounds it claimed are now in the public domain and can be practiced by any entity without infringing this specific patent. How Does U.S. Patent 6,280,705 Relate to Existing and Emerging Therapies? U.S. Patent 6,280,705 is intrinsically linked to the development and commercialization of erythropoiesis stimulating agents (ESAs). Therapies that directly utilize recombinant human erythropoietin (rHuEPO) or its analogs for treating anemia, particularly anemia associated with chronic kidney disease (CKD) and cancer chemotherapy, fall under the purview of this patent’s claims. The patent's expiration in December 2018 has significant implications for the market: Generic and Biosimilar Competition: The expiration of foundational patents like this one often paves the way for the entry of generic drugs or biosimilars. While the patent covered methods of use and specific compounds (analogs and muteins), the expiration of its term removed the primary legal barrier for competitors to offer similar therapies or utilize the patented methods. Amgen's Dominance: During its patent life, Amgen was a dominant player with its EPO product, Epogen (epoetin alfa), and later Aranesp (darbepoetin alfa). The patent likely protected Amgen's methods of use and development of novel EPO analogs. Emerging Therapies: Newer approaches to stimulating erythropoiesis, such as hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (e.g., roxadustat, vadadustat, daprodustat), offer an alternative mechanism of action independent of direct EPO receptor binding and JAK/STAT activation as described in this patent. These therapies represent a distinct technological class that likely operates outside the scope of expired patent 6,280,705. However, they still target the same therapeutic outcomes. The patent's scope, particularly claims 21-39 which broadly cover JAK/STAT pathway modulation via EPO receptor binding, may have had implications for research into other signaling pathways or agents that interact with the EPO receptor or downstream JAK/STAT components. What is the Patent Landscape Surrounding U.S. Patent 6,280,705? The patent landscape surrounding U.S. Patent 6,280,705 is rich and complex, primarily driven by the significant clinical and commercial importance of erythropoiesis stimulating agents (ESAs). Amgen Inc. has historically been a central figure in this landscape, holding numerous patents related to EPO and its applications. Key aspects of the patent landscape include: Composition of Matter Patents: Earlier and potentially overlapping patents would have covered the composition of matter for recombinant EPO (e.g., epoetin alfa) and specific analogs. These patents would have been the primary barrier to entry for competitors prior to their expiration. Method of Use Patents: U.S. Patent 6,280,705 is a prime example of a method of use patent. It claims specific ways to utilize ESAs for therapeutic benefits. As such, even after composition of matter patents expire, method of use patents can continue to provide market exclusivity. Patents on Analogs and Muteins: Significant patent activity has focused on developing and patenting EPO analogs and muteins with improved pharmacokinetic properties, reduced immunogenicity, or altered efficacy. Darbepoetin alfa (Aranesp), developed by Amgen, is an example of such an analog that was protected by its own patent portfolio. Patents on Delivery Systems and Formulations: Patents also exist for novel formulations, delivery devices (e.g., pre-filled syringes), and administration regimens designed to improve patient compliance, efficacy, and safety. Patents on Biosimilars and Generics: Following the expiration of key composition of matter and method of use patents, the landscape shifts towards patents covering biosimilar versions of EPO. These patents often focus on the specific manufacturing processes, analytical characterization, and clinical trial data required to demonstrate biosimilarity. Patents on Alternative Mechanisms: The development of non-peptide HIF-PH inhibitors represents a new wave of innovation. Patents in this area protect novel chemical entities and their methods of use, offering a distinct therapeutic modality. These patents are crucial for companies investing in these alternative pathways. Key Players and Their Patent Activity: Amgen Inc.: The assignee of 6,280,705, Amgen has been a leader in EPO-based therapies and holds a substantial portfolio of patents covering EPO, its analogs, and methods of use. Johnson & Johnson: Developed and markets Procrit (epoetin alfa), an ESA that has been subject to extensive patent litigation and licensing agreements. Other Biologics/Pharma Companies: Numerous companies have developed or are developing ESAs or biosimilars, each with their own patent strategies. Examples include Pfizer (Inflectra, which is for infliximab but illustrates biosimilar patenting), and companies developing biosimilars of epoetin alfa. Biotechnology Companies: Companies focused on novel drug discovery may hold patents on new EPO receptor agonists or modulators, or entirely new classes of drugs targeting erythropoiesis. The expiration of U.S. Patent 6,280,705 removes one layer of protection for methods related to EPO signaling, potentially facilitating broader use of existing ESA therapies and increasing the potential for biosimilar competition. However, a comprehensive understanding of freedom to operate requires analysis of the entire patent landscape, including patents on specific molecules, manufacturing processes, and newer therapeutic modalities. What are the Implications of the Patent's Expiration for Amgen Inc. and Competitors? The expiration of U.S. Patent 6,280,705 on December 10, 2018, has several direct implications for Amgen Inc. and its competitors: For Amgen Inc.: Loss of Method Exclusivity: Amgen no longer holds exclusive rights to the methods of using ESAs as defined in this patent for stimulating erythropoiesis, increasing red blood cells, producing hemoglobin, and treating anemia or myelodysplastic syndromes. Increased Competition for Existing Products: While Amgen’s primary EPO products (Epogen and Aranesp) may be protected by other patents or have benefited from market leadership and brand loyalty, the expiration of this method patent opens the door for competitors to market biosimilars or generics that employ these methods. This can lead to price erosion and reduced market share. Shift in R&D Focus: With foundational patents expiring, Amgen would have likely shifted its R&D focus towards next-generation therapies or different therapeutic areas, potentially exploring mechanisms beyond direct EPO receptor agonism or developing novel agents with improved profiles. The company has invested in novel mechanisms for anemia, such as HIF-PH inhibitors. For Competitors: Freedom to Operate: Competitors, including generic manufacturers and companies developing biosimilars, now have a clearer path to market for products that utilize the methods protected by this patent. This expands their ability to offer treatments for anemia and related conditions. Market Entry for Biosimilars: The expiration of this patent, alongside other relevant patents, is a crucial step in the regulatory and commercial pathway for biosimilar EPO products. It allows for the development and approval of biosimilars that can compete with Amgen's established ESA therapies. Increased Innovation in Alternative Mechanisms: While this patent protected EPO-centric methods, its expiration may indirectly spur further innovation in entirely novel approaches to erythropoiesis stimulation, such as HIF-PH inhibitors, as companies seek to differentiate themselves or find pathways not covered by expired patents. Potential for Litigation on Other Patents: Competitors must still navigate the broader patent landscape. While 6,280,705 has expired, other patents held by Amgen or other entities covering specific EPO molecules, manufacturing processes, or novel formulations may still be in force, leading to potential patent litigation. The expiration of U.S. Patent 6,280,705 signifies a transition in the market for anemia treatments. It marks the end of patent protection for specific methods of using ESAs, thereby intensifying competition and potentially accelerating the adoption of biosimilar therapies and the development of novel treatment modalities. Key Takeaways U.S. Patent 6,280,705, held by Amgen Inc., expired on December 10, 2018. The patent protected methods for modulating signal transduction pathways, specifically the JAK/STAT pathway, primarily through the use of erythropoiesis stimulating agents (ESAs) like erythropoietin. Key claims covered methods for stimulating erythropoiesis, increasing red blood cell production, producing hemoglobin, and treating anemia and myelodysplastic syndromes using ESAs. Broader claims addressed modulating signal transduction via EPO receptor binding and JAK activation. The patent's expiration removed a significant barrier for competitors, enabling the use of these methods by generic and biosimilar manufacturers. This expiration intensifies competition for existing ESA therapies and may further stimulate innovation in alternative mechanisms for treating anemia. Frequently Asked Questions Can I now manufacture and sell recombinant human erythropoietin (rHuEPO) in the U.S. without any patent concerns? No. While U.S. Patent 6,280,705 has expired, other patents may cover the composition of matter of rHuEPO itself, specific manufacturing processes, formulations, or novel analogs. A comprehensive freedom-to-operate analysis is required. What specific therapeutic areas were most directly impacted by the expiration of this patent? The expiration most directly impacts the treatment of anemia (including anemia of chronic kidney disease and chemotherapy-induced anemia), myelodysplastic syndromes, and any other conditions where stimulating erythropoiesis via EPO receptor activation is a therapeutic strategy. Does the expiration of this patent mean that Amgen's Epogen® and Aranesp® are no longer protected? This patent protected specific methods of use. Amgen's products may still be protected by other patents covering their specific molecular structure, manufacturing, or formulations, which could remain in force. Are newer anemia treatments like HIF-PH inhibitors covered by this patent? No. Therapies like HIF-PH inhibitors (e.g., roxadustat, vadadustat) operate through a different mechanism of action that does not directly involve the EPO receptor binding or JAK/STAT activation as described in U.S. Patent 6,280,705. Their patent protection would be based on separate intellectual property. If I am developing a new EPO analog, does the expiration of 6,280,705 grant me freedom to operate? Not necessarily. While this patent covers methods, a new EPO analog would need to be assessed against any existing patents claiming the composition of matter of that specific analog, as well as any remaining method of use patents that are still in force. Cited Sources [1] Amgen Inc. (2001). U.S. Patent No. 6,280,705. Washington, D.C.: U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	281183	⤷ Start Trial
Australia	4922196	⤷ Start Trial
Australia	5199701	⤷ Start Trial
Australia	694135	⤷ Start Trial
Australia	731099	⤷ Start Trial
Australia	731671	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,280,705

Summary for Patent: 6,280,705